| Patient | Mumtaz Mahal |
|---|---|
| Date of birth | 1988-04-27 |
| Identifiers | MRN HR-RE006-SYN; SSN (made up) 000-06-7184 |
| Document date | 2026-06-02 |
| Author | Farzana Qureshi-Lindholm, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Prenatal visit at 34 weeks after six weeks of travel; growth scan and birth planning. [S]
Mumtaz Mahal returns at 34 weeks 2 days, three days after coming back from six weeks of travel with her family. The visits planned at 30 and 32 weeks did not take place: the family moved several times and no clinic was arranged, and no blood pressure was checked while she was away. She has felt well. She has had no headache, visual change, upper abdominal pain, swelling of the face or hands, breathlessness, bleeding, leaking fluid, or regular contractions; she has occasional painless tightenings, and the baby moves often. She took aspirin and folic acid throughout. The test-of-cure urine culture sent before she left grew nothing. She is staying in the city until the birth. She had the growth scan this morning. She has thought about the future and says she wants her body to rest after this baby. [S]
| Element | Detail |
|---|---|
| Travel | Six weeks away; the 30- and 32-week visits were missed |
| Symptoms | None of preeclampsia; occasional painless tightenings |
| Fetal movement | Frequent |
| Urine | Test-of-cure culture: no growth |
| Plans | Staying near the hospital until the birth |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Well; no fever |
| Cardiovascular | Negative | No breathlessness or palpitations |
| Neurological | Negative | No headache or visual change |
| Gastrointestinal | Negative | No upper abdominal pain or vomiting |
| Genitourinary | Negative | No bleeding, leaking fluid, or urinary symptoms |
| Psychiatric | Negative | Calm and hopeful; EPDS 5 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-06 | active | S |
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day | One tablet every other morning with water or orange juice, apart from tea and calcium | Oral route | 2026-01-06 to 2026-02-03 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 2026-01-06 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily for 5 days | One capsule twice daily with food for 5 days | Oral route | 2026-03-24 to 2026-03-29 | completed | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 2026-02-03 to 2026-02-03 | completed | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 2026-03-03 to 2026-03-03 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-02 | Body height | 157 | cm | S |
| 2026-06-02 | Body weight | 68 | kg | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 2026-06-02 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-06-02 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-06-02 | Heart rate | 88 | /min | S |
| 2026-06-02 | Respiratory rate | 16 | /min | S |
| 2026-06-02 | Body temperature | 36.8 | Cel | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-02 | Hemoglobin [Mass/volume] in Blood | 11.8 | g/dL | 11-15 g/dL | Normal | S |
| 2026-06-02 | Platelets [#/volume] in Blood by Automated count | 228 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-02 | Total score [EPDS] | 5 | {score} | S | ||
| 2026-06-02 | Fetal Body weight estimated by US | 2380 | g | About the 45th centile for 34 weeks | Normal | S |
Vital signs recorded on 2026-06-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Abdomen | Fundal height 34 cm; cephalic by palpation; non-tender |
| Fetal | Scan: cephalic, estimated weight 2380 g (about the 45th centile), normal amniotic fluid; fetal heart 140 per minute |
| Extremities | Trace ankle edema; no calf tenderness |
| Urine dipstick | Protein negative |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12 | active | confirmed | O09.529 | S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic. |
| Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living children | active | confirmed | O09.40 | S — Synthetic modern problem anchored to her documented thirteen earlier births. |
| Short interpregnancy interval: conception about five and a half months after her last birth | active | confirmed | O09.899 | S — Synthetic modern problem anchored to the documented fourteen months between her last two births. |
| Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mL | active | confirmed | O99.019 | S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis. |
| Acute cystitis in pregnancy at 24 weeks: dysuria and frequency, no fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; treated and resolved | resolved | confirmed | O23.12 | S — Synthetic intercurrent infection at an unscheduled visit; common in pregnancy and in multiparous women. It echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 112/70 mmHg; urine protein negative |
| Examination | Blood pressure and fetal checks at 30 and 32 weeks | Every two weeks from 28 to 36 weeks | Deferred | Missed: the 30- and 32-week visits did not take place during six weeks of family travel, and no blood pressure was recorded. No harm found today: blood pressure 112/70 mmHg, no proteinuria, no symptoms, and normal growth on the scan. Corrective action: weekly visits until the birth, a home blood pressure cuff with readings to call in, and she will stay near the hospital |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 140 per minute; fundal height 34 cm; cephalic |
| Examination | Weight gain | Every prenatal visit | Completed today | 68.0 kg, up 9.4 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 11.8 g/dL: anemia corrected before delivery; platelets 228 |
| Imaging | Third-trimester growth scan | At about 32 to 34 weeks | Completed today | Estimated weight 2380 g, about the 45th centile; cephalic; normal fluid |
| Laboratory | Urine culture test of cure | One to two weeks after treatment | Completed today | No growth (sent at the 27-week visit) |
| Laboratory | Group B streptococcus culture | At 36 0/7 to 37 6/7 weeks | Due | At the 36-week visit |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Completed today | 5; item 10 scored 0 |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly; continue until delivery |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Completed today | Medium risk from grand multiparity; written plan agreed: hospital birth, oxytocin, quantitative blood loss, tranexamic acid within 3 hours if hemorrhage occurs |
| Referral | Anesthesia consultation | In the third trimester for a patient at increased risk of hemorrhage | Due | Booked for 36 weeks |
| Self-management | Postpartum contraception and interpregnancy interval | Before delivery | Completed today | Etonogestrel implant before discharge; at least 18 to 24 months before any future pregnancy |
Goal progress:
Guideline basis: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Practice Bulletin No. 183: Postpartum Hemorrhage (2017); WHO recommendations for the prevention and treatment of postpartum haemorrhage (2012); WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017); Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial (2017); Obstetric Care Consensus No. 8: Interpregnancy Care (2019); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024)
Follow-up: Weekly prenatal visits from next week until the birth; induction at 39 weeks at the hospital. [S]